Please assess the completion status of the following clinical trial:

Trial Title: Mesenchymal Stem Cells in Patients With Type 1 Diabetes Mellitus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of Type 1 Diabetes according to the American Diabetes Association criteria for a period less than four months.~* Pancreatic Autoimmunity (positive anti-glutamic acid decarboxylase \[GAD\]; and/or Islet antigen 2 \[anti-IA2\]).~Exclusion Criteria:~* Clinical evidence of malignancy or prior history.~* Pregnancy or desire to become pregnant within 12 months of the study.~* Breastfeeding .~* HIV(+), Hepatitis B (+), Hepatitis C(+).~* Diabetic ketoacidosis at diagnosis.~* Glomerular filtration rate less than 60ml/min.~* Use of immunosuppressors or glucocorticoids.

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: 35 Years
- Healthy Volunteers: f

Study Arms:
- Adipose tissue-derived stem/stromal cells (Type: EXPERIMENTAL): Safety of adipose tissue-derived stem/stromal cells (ASCs) for 24 months in patients with recente onset type 1 diabetes.
- Daily 2000 UI of daily oral cholecalciferol (Type: EXPERIMENTAL): To investigate the efficacy of daily 2000 UI Cholecalciferol/day for 24 months in patients with recente onset type 1 diabetes.

Based on this trial design, predict the completion outcome and termination type (if applicable).